Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) Other Non Operating Income (2022 - 2025)

Historic Other Non Operating Income for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $97000.0.

  • Century Therapeutics' Other Non Operating Income fell 6120.0% to $97000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $278000.0, marking a year-over-year increase of 1880.34%. This contributed to the annual value of $354000.0 for FY2024, which is 19242.82% up from last year.
  • Latest data reveals that Century Therapeutics reported Other Non Operating Income of $97000.0 as of Q3 2025, which was down 6120.0% from $113000.0 recorded in Q2 2025.
  • Century Therapeutics' Other Non Operating Income's 5-year high stood at $4.4 million during Q4 2022, with a 5-year trough of -$194000.0 in Q1 2023.
  • Moreover, its 4-year median value for Other Non Operating Income was $11000.0 (2024), whereas its average is $321133.3.
  • Per our database at Business Quant, Century Therapeutics' Other Non Operating Income tumbled by 382000.0% in 2023 and then skyrocketed by 198333.33% in 2024.
  • Quarter analysis of 4 years shows Century Therapeutics' Other Non Operating Income stood at $4.4 million in 2022, then tumbled by 100.34% to -$15000.0 in 2023, then surged by 806.67% to $106000.0 in 2024, then decreased by 8.49% to $97000.0 in 2025.
  • Its Other Non Operating Income stands at $97000.0 for Q3 2025, versus $113000.0 for Q2 2025 and -$38000.0 for Q1 2025.